Primary sclerosing cholangitis and the risks of posttransplant lymphoproliferative disorder-Reference-Cited by-同舟云学术

Primary sclerosing cholangitis and the risks of posttransplant lymphoproliferative disorder

Published:2024-02-29 Issue:6 Volume:30 Page:567-569
ISSN:1527-6465
Container-title:Liver Transplantation
language:en
Short-container-title:

Author:

Hussain Nasir¹²³,Ferguson James¹²,Hirschfield Gideon M.⁴^ORCID,Trivedi Palak J.¹²³^ORCID

Affiliation:

1. Centre for Liver and Gastrointestinal Research University of Birmingham, National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre (BRC), United Kingdom

2. Liver Unit University Hospitals Birmingham, Birmingham, United Kingdom

3. Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom

4. Division of Gastroenterology and Hepatology, Toronto Centre for Liver Disease, University of Toronto, Toronto, Ontario, Canada

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference16 articles.

1. Recent advances in clinical practice: Epidemiology of autoimmune liver diseases;Trivedi;Gut,2021

2. Liver transplantation for primary sclerosing cholangitis (PSC) with or without inflammatory bowel disease (IBD)—A European Society of Organ Transplantation (ESOT) consensus statement;Carbone;Transpl Int,2023

3. Recurrent PSC in the A2ALL study: Comparison of risk factors between living and deceased donor recipients;Gordon;Liver Transpl,2016

4. Clinical outcomes of donation after circulatory death liver transplantation in primary sclerosing cholangitis;Trivedi;J Hepatol,2017

5. Systematic review with meta-analysis: Risk factors for recurrent primary sclerosing cholangitis after liver transplantation;Steenstraten;Aliment Pharmacol Ther,2019